Mills Kenneth T. - 24 Jun 2021 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
President and CEO, Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
24 Jun 2021
Net transactions value
-$217,905
Form type
4
Filing time
28 Jun 2021, 16:18:52 UTC
Next filing
15 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $16,920 +4,500 +1.6% $3.76* 285,484 24 Jun 2021 Direct F1
transaction RGNX Common Stock Sale $180,090 -4,500 -1.6% $40.02 280,984 24 Jun 2021 Direct F1, F2
transaction RGNX Common Stock Options Exercise $5,640 +1,500 +0.53% $3.76* 282,484 25 Jun 2021 Direct F1
transaction RGNX Common Stock Sale $60,375 -1,500 -0.53% $40.25 280,984 25 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -4,500 -1.6% $0.000000 270,500 24 Jun 2021 Common Stock 4,500 $3.76 Direct F1, F3
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -1,500 -0.55% $0.000000 269,000 25 Jun 2021 Common Stock 1,500 $3.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.